• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Poll: How Much Progress With Biosimilars Has the United States Made?


With 20 biosimilar launches in the United States since 2015, opinions vary as to the strength of utilization.

Which of the following best describes your assessment of the US biosimilar marketplace?

Biosimilar uptake has exceeded expectations for savings and access.
The United States lags other countries on biosimilar uptake.
The progress with biosimilar absorption has been satisfactory.
Progress with biosimilars has been uneven across drug categories.
© 2024 MJH Life Sciences

All rights reserved.